CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Ted Hibben as senior vice president, corporate development. Mr. Hibben brings to Catabasis over 20 years of experience in business and corporate development, strategy, fundraising and M&A.
“I am eager to identify new opportunities to drive new therapies for patients and create the most value for our shareholders.”
“Ted brings to Catabasis a successful track record of building the value of innovative product platforms, an ideal fit for our SMART linker platform that has already produced product candidates in multiple disease areas,” said Rick Modi, chief business officer of Catabasis. “We look forward to his contributions as we advance CAT-2054, an oral SREBP modulator that targets the inhibition of PCSK9, HMG-CoA reductase, and ATP citrate lyase, for hypercholesterolemia and CAT-1004, an oral NF-kB modulator, for Duchenne muscular dystrophy (DMD).”
“The Catabasis technology platform has the potential to create therapeutics that impact multiple targets in a disease pathway to produce synergistic efficacy,” commented Mr. Hibben. “I am eager to identify new opportunities to drive new therapies for patients and create the most value for our shareholders.”
Prior to joining Catabasis, Mr. Hibben was senior vice president, corporate development at Ensemble Therapeutics, where he formed four multi-target discovery and development-stage collaborations with pharmaceutical companies, generating over $1 billion in potential milestone payments for programs emerging from Ensemble’s macrocycle library platforms. Previously, Mr. Hibben was chief business officer at Cequent Pharmaceuticals, where he played an instrumental role in its $46M 2010 merger with MDRNA, Inc. (now Marina Biotech), and was vice president, business development and alliance management at Coley Pharmaceutical Group, where he sourced and/or managed nine development alliances and led the sale of Coley to Pfizer for $233M in 2008. Ted holds an MBA from Harvard University and an AB from Dartmouth College.
About Catabasis
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company’s technology and pipeline of drug candidates, please visit www.catabasis.com.
Contacts
Corporate and Media
Catabasis Pharmaceuticals Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
Help employers find you! Check out all the jobs and post your resume.
